Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping

European Urology

Volumn 72, Issue 1, 2017, Pages 78-83

  Vidal, Adriana C ^a   Freedland, Stephen J ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Active surveillance; Molecular subtype of prostate cancer; Obesity; Prostate cancer; Race

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BLACK PERSON; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; HUMAN; MEDLINE; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; REVIEW; CANCER GRADING; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; MALE; MOLECULAR DIAGNOSIS; PHENOTYPE; PREDICTIVE VALUE; PROSTATE TUMOR; RISK ASSESSMENT; RISK FACTOR; TUMOR INVASION; WATCHFUL WAITING;

BIOMARKERS, TUMOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM GRADING; NEOPLASM INVASIVENESS; OBESITY; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; WATCHFUL WAITING;

EID: 85008970562     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.10.011     Document Type: Review

References (27)

1. Allott, E.H., Masko, E.M., Freedland, S.J., Obesity and prostate cancer: weighing the evidence. Eur Urol 63 (2013), 800–809.
2. Kane, C.J., Im, R., Amling, C.L., et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology 76 (2010), 695–700.
3. Ploussard, G., de la Taille, A., Bayoud, Y., et al. The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance. Eur Urol 61 (2012), 356–362.
4. Truong, M., Slezak, J.A., Lin, C.P., et al. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer 119 (2013), 3992–4002.
5. de Cobelli, O., Terracciano, D., Tagliabue, E., et al. Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance. Urol Oncol, 33, 2015 201.e1–8.
6. Bhindi, B., Kulkarni, G.S., Finelli, A., et al. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. Eur Urol 66 (2014), 841–848.
7. Muller, R.L., Gerber, L., Moreira, D.M., et al. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. Eur Urol 63 (2013), 1115–1121.
8. Ho, T., Gerber, L., Aronson, W.J., et al. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. Eur Urol 62 (2012), 910–916.
9. Okotie, O.T., Aronson, W.J., Wieder, J.A., et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 171 (2004), 2260–2264.
10. Howlader N, Noone AM, Krapcho M, et al, editors. SEER cancer statistics review, 1975-2012. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2012.
11. Barrington, W.E., Schenk, J.M., Etzioni, R., et al. Difference in association of obesity with prostate cancer risk between US African American and non-Hispanic white men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol 1 (2015), 342–349.
12. Culp, S., Porter, M., The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. BJU Int 104 (2009), 1457–1461.
13. Allott, E.H., Howard, L.E., Aronson, W.J., et al. Racial differences in the association between preoperative serum cholesterol and prostate cancer recurrence: results from the SEARCH database. Cancer Epidemiol Biomarkers Prev 25 (2016), 547–554.
14. Allott, E.H., Howard, L.E., Song, H.J., et al. Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiotherapy. Cancer Epidemiol Biomarkers Prev 23 (2014), 2404–2412.
15. Spangler, E., Zeigler-Johnson, C.M., Coomes, M., Malkowicz, S.B., Wein, A., Rebbeck, T.R., Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. J Urol 178 (2007), 1939–1944.
16. Su, L.J., Arab, L., Steck, S.E., et al. Obesity and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Cancer Epidemiol Biomarkers Prev 20 (2011), 844–853.
17. Hayes, R.B., Ziegler, R.G., Gridley, G., et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 8 (1999), 25–34.
18. Park, S.Y., Haiman, C.A., Cheng, I., et al. Racial/ethnic differences in lifestyle-related factors and prostate cancer risk: the Multiethnic Cohort Study. Cancer Causes Control 26 (2015), 1507–1515.
19. Jayachandran, J., Banez, L.L., Aronson, W.J., et al. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 115 (2009), 5263–5271.
20. Pettersson, A., Lis, R.T., Meisner, A., et al. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst 105 (2013), 1881–1890.
21. Rubin, M.A., Maher, C.A., Chinnaiyan, A.M., Common gene rearrangements in prostate cancer. J Clin Oncol 29 (2011), 3659–3668.
22. Egbers, L., Luedeke, M., Rinckleb, A., et al. Obesity and prostate cancer risk according to tumor TMPRSS2:ERG gene fusion status. Am J Epidemiol 181 (2015), 706–713.
23. Gumuskaya, B., Gurel, B., Fedor, H., et al. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion. Prostate Cancer Prostatic Dis 16 (2013), 209–215.
24. Mithal, P., Allott, E., Gerber, L., et al. PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer. Int J Urol 21 (2014), 1209–1214.
25. Zhao, H., Logothetis, C.J., Gorlov, I.P., Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression. Prostate Cancer Prostatic Dis 13 (2010), 252–259.
26. Ross, A.E., D'Amico, A.V., Freedland, S.J., Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer. Prostate Cancer Prostatic Dis 19 (2016), 1–6.
27. Kalaany, N.Y., Sabatini, D.M., Tumours with PI3K activation are resistant to dietary restriction. Nature 458 (2009), 725–731.